Materials and methods
We aim to include 40 patients diagnosed with invasive ductal carcinoma, who will undergo neoadjuvant chemotherapy before surgery. We are in process of collecting tumor tissue biopsies and quantifying, by flow cytometry, and separating, by FACS, the CSCs. We will define CSCs genetic profiles and correlate them with pathological response to the treatment. Biopsies have been collected from five patients to date; from these samples, CSCs were sorted and RNA was extracted and stored. We are following patients for their clinical progress.
Results
To date, we did not observe statistical differences in the percentage of CSCs in these five samples. We expect to find transcriptional differences between CSCs in tumors from patients who respond to neoadjuvant chemotherapy and from patients who do not respond to treatment regimens.
Conclusions
Although our preliminary data did not show differences, we expect a slightly different percentage of CSCs in tumor samples from responders vs. non-responders, in a larger sample set. However, CSCs transcriptome differences between the two groups of patients may yield a better understanding of neoadjuvant chemotherapy resistance, preventing unnecessary and costly treatment for many patients.
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